The Medicines and Healthcare products Regulatory Agency (MHRA) has concluded its review of the PATHWAYS clinical trial, confirming that a revised protocol now meets the necessary regulatory standards. Concurrently, the Health Research Authority (HRA) has granted ethical approval for the updated trial, which focuses on the use of puberty-suppressing medication in children and young people experiencing gender incongruence across the UK.
The modifications to the trial protocol introduce enhanced safeguards designed to bolster participant safety. These include the establishment of minimum ages for entry into the trial, alongside more clearly defined measures for discontinuing treatment should safety concerns arise. Specific areas of focus for these discontinuation criteria encompass bone health, cognitive function, and vaginal bleeding. Furthermore, the updated protocol provides more comprehensive information to participants regarding fertility preservation, a critical aspect of care for those undergoing such treatments.
During the scientific dialogue process, the MHRA sought independent expert advice from the Commission on Human Medicines. This consultation focused specifically on the safety of participants and the adequacy of the proposed strengthened safeguards within the trial. The sponsor also submitted the modified protocol to the relevant Research Ethics Committee, facilitated by the Health Research Authority, ensuring a thorough ethical review of the changes.
The PATHWAYS clinical trial is a significant UK-wide study designed to gather evidence on how the timing of puberty-suppressing medication affects a range of outcomes. These include quality of life, mental health, physical development, cognitive function, and the level of gender-related distress experienced by participants. The overarching goal is to contribute to a more robust understanding of the impacts of these interventions.
Despite these approvals, recruitment for the PATHWAYS clinical trial is not expected to commence until 1 August 2026. This delay is attributed to ongoing legal proceedings, which have paused the start date for participant enrolment. This timeline allows for further preparation and resolution of external factors before the trial can actively begin to gather data.